March is Kidney Cancer Awareness Month! Over 400,000 people worldwide will be diagnosed with kidney cancer this year. In the United States, 500,000 Americans are living with kidney cancer and 70,000 more will be diagnosed. March is our month to raise awareness about the impact of this disease and the need for more research. Over the last few months, the world has been captivated by shared pu...
November 19, 2021 KCCure is offering a grant totaling $50,000 for a project focused on innovative scientific research in chromophobe renal cell carcinoma (RCC). Chromophobe RCC is a rare subtype of kidney cancer accounting for roughly 5 percent of RCC tumors. When discovered early, this histological type is less likely to spread to other parts of the body. However, once the disease becomes m...
On August 10, 2021, the Food and Drug Administration approved the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Pembrolizumab is an anti-PD-1 checkpoint inhibitor that helps the immune system detect and fight tumor cells. Lenvatinib is an anti-angiogenic targeted therapy that inhibits growth of...
What is No Tie July? No Tie July is our annual fundraising effort where we raise $50,000 – one year of research funding – in just one month! Since our launch in 2016, this fundraising effort has helped us to award $400,000 in direct research grants. How Can You Participate? 1.) Designate a Research Priority This year, we are excited to unveil a new feature of our Research Grant Program...